Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05812274 · ClinicalTrials.gov registry record · NA
Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients
A NA study, sponsored by Columbia University.
- Terminated
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT05812274: Clinical Trial NA study, sponsored by Columbia University.
NCT05812274 is a NA study that was terminated before completion, run by Columbia University. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05812274, a NA study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this trial is to study the effectiveness of the AprictyRxTM care service to improve treatment outcomes of ethnic/racial minority N.S.C.L.C. patients receiving standard of care immunotherapy, and reduce the frequency of healthcare system interactions.
Primary Outcome
Two focus group discussions (FGDs), stratified on a Likert-type scale based on the frequency of utilization, to determine factors related to usage of ApricityCare app and utilization of the CARE monitoring service (Run-in phase). To assess factors related to suboptimal and optimal use of the ApricityCare app and the CARE monitoring service, collectively "the Apricity CARE program".
Interventions
- OTHER Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2025-10-24 |
| Phase | NA |
Why NCT05812274 stopped before completion
NCT05812274 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation is the first listed.
NCT05812274 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05812274 about?
NCT05812274 is a clinical study titled "Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients". The purpose of this trial is to study the effectiveness of the AprictyRxTM care service to improve treatment outcomes of ethnic/racial minority N.S.C.L.C. patients receiving standard of care immunotherapy, and reduce the frequency of healthcare system interactions.
What is the current status of trial NCT05812274?
This trial is currently terminated. It is a NA study. The enrollment target is 30 participants. The study started on 2023-05-31. Estimated completion is 2025-10-24.
What interventions are being tested in trial NCT05812274?
The interventions under investigation include: Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation (OTHER).
Who is sponsoring clinical trial NCT05812274?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05812274's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI